Allergan plc , a leading global pharmaceutical company, is pleased to announce that its manuscript, “Fluctuations in Episodic and Chronic Migraine Status Over the Course of One Year: Implications for Diagnosis, Treatment and Clinical Trial Design,” has been selected as the 2017 Enrico Greppi Award Winner. The Italian Society for the Study of Headaches (SISC) grants the annual Award to the best unpublished original paper dealing with clinical, epidemiological, genetic, pathophysiological or therapeutic aspects of headache, in memory of Enrico Greppi, a pioneer and expert in the study of headache.
“We are honored to receive this prestigious award and the recognition of the importance of gaining a data-driven understanding of chronic migraine to improve classification, diagnosis and clinical trial design,” says Richard Lipton, MD, Vice Chair of Neurology, Albert Einstein College of Medicine, and an author on the paper. “There is a traditional bright line of 15 headache days that separates people with episodic migraine from those with chronic migraine, but people with migraine experience striking fluctuations in the frequency of their headache attacks. Therefore, days alone may not be sufficiently stable to distinguish between episodic and chronic migraine. More data is needed to fully understand the underlying biological differences.”
The award-winning manuscript, which was published in The Journal of Headache and Pain and will be presented at the 11th European Headache Federation (EHF) Congress in Rome, includes findings from the longitudinal Chronic Migraine Epidemiology and Outcomes (CaMEO) Study, which recruited nearly 17,000 individuals with migraine from a web-based panel, to complete a series of surveys for more than one year. It was purposely designed to characterize natural migraine disease course; quantify its societal, familial, and economic impact; and provide an evidence-based foundation to improve migraine care.
“For decades, Allergan has been investing in research that continues to uncover new data about headache medicine and improve our understanding of the disease. We’re proud to be recognized with this prestigious award and share our latest data on a global stage,” said David Nicholson, Chief Research & Development Officer at Allergan. “We congratulate the authors on this honor and are grateful for their shared commitment to the future of headache research.”
Allergan will also present six additional abstracts on Chronic Migraine and the Company’s Chronic Migraine treatment. Beyond the award lecture, highlights include three podium presentations on findings from the CaMEO study on comorbidities of migraine, the REPOSE study on the safety and effectiveness of BOTOX® (onabotulinumtoxinA) for the treatment of Chronic Migraine, and the FORWARD study comparing the tolerability profile of BOTOX® and topiramate for the preventive treatment of Chronic Migraine. Allergan will also present four posters containing data from CaMEO and FORWARD studies, and the diagnosis of patients with Chronic Migraine.
Allergan, a leader in the Chronic Migraine space, markets BOTOX® (onabotulinumtoxinA) the first and only FDA-approved, preventive treatment for adult Chronic Migraine patients since it was approved in 2010. Allergan is also advancing its migraine program with two investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine. Allergan’s CGRPs, ubrogepant in Phase III for the acute treatment of migraine and atogepant in Phase II for the prevention of migraine, are expected to be the first oral CGRP receptor antagonists to market.
Funding for the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study was provided by Allergan plc.
About Allergan plc
Allergan plc headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 55+ mid-to-late stage pipeline programs currently in development.
Allergan’s success is powered by our more than 18,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com
Allergan:
Investors:
Daphne Karydas
(862) 261-8006
Media:
Mark Marmur
(862) 261-7558
